Skip Navigation


Rheumatology Advance Access originally published online on May 13, 2008
Rheumatology 2008 47(7):1107; doi:10.1093/rheumatology/ken173
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/7/1107-a    most recent
ken173v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bansback, N.
Right arrow Articles by Watson, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bansback, N.
Right arrow Articles by Watson, K.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Comment on: Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry: reply

N. Bansback1, A. Brennan2, D. Symmons3, R. Nixon4, J. Madan2, M. Harrison3 and K. Watson3

1Centre for Health Evaluation and Outcome Sciences, St Paul's Hospital, Vancouver, Canada, 2Health Economics and Decision Science, School of Health and Related Research (ScHARR), The University of Sheffield, Sheffield, 3Arthritis Research Campaign Epidemiology Unit, The University of Manchester, Manchester and 4MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, UK

Correspondence to: N. Bansback, Centre for Health Evaluation and Outcomes Sciences - Pharmaeconomics group, 620B-1081 Burrard St Vancouver, BC V6Z 1Y6, Canada. E-mail: nbansback@cheos.ubc.ca

The first 10% of the full text of this article appears below.

SIR, We thank Dr Von Vollenhoven for his interest in our paper. The questions [1] he raises about our article that examined the cost–effectiveness of biologics using the British Society for Rheumatology Biologics Registry (BSRBR) [2] provide an excellent opportunity to describe why decision modelling should be used in calculating a majority of cost–effectiveness . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?